Stockscreener 앱 받기
37.45
1.15%
0.427
시간 외 거래:
37.46
0.013
+0.03%
Cogent Biosciences Inc 주식(COGT)의 최신 뉴스
Vanguard Group Inc. Has $111.40 Million Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Rafferty Asset Management LLC Purchases 57,139 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences: Trio Of Approvals Beckon For Lead DrugStill Bullish (NASDAQ:COGT) - Seeking Alpha
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility - Yahoo Finance
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity - Yahoo Finance
Cogent Biosciences (COGT) Reveals Promising Results in Latest Be - GuruFocus
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval - Insider Monkey
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Cogent Biosciences Reports Promising 48-Week Results for Bezuclastinib in NonAdvanced Systemic Mastocytosis Patients - Quiver Quantitative
Cogent Biosciences Highlights Additional Data with Six - GlobeNewswire
A Look At Cogent Biosciences (COGT) Valuation After A Strong One Year Shareholder Return - Sahm
Cogent Biosciences, Inc. (COGT) - DirectorsTalk Interviews
Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval - Finviz
How Do Cogent Biosciences’ Growing Losses and ESOP Shelf Shape Its Capital Strategy Narrative (COGT)? - simplywall.st
COGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk - Sahm
Cogent Biosciences, Inc. $COGT Stock Position Cut by NEOS Investment Management LLC - MarketBeat
Cogent Biosciences, Inc. (COGT) Stock Analysis: Biotechnology Innovator With 40% Upside Potential - DirectorsTalk Interviews
Quarterly Risk: What is Cogent Biosciences Incs 5 year growth outlookMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million - AOL.com
Readystate Asset Management LP Takes $714,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Piper Sandler raises Cogent stock price target on drug launch outlook By Investing.com - Investing.com Australia
Piper Sandler raises Cogent stock price target on drug launch outlook - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
COGT Sees a Boost in Price Target and Maintained Overweight Rati - GuruFocus
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib NDA Filings Earnings Update And New Shelf Registration - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Progress Versus Market Expectations This Quarter - Kalkine Media
(COGT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Cogent Biosciences (COGT) Reports Strong Cash Position by Year-E - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
COGT Plans to Launch Bezuclastinib Following Key Regulatory Subm - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Issues Earnings Results - MarketBeat
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
BRIEF-Cogent Biosciences Q4 Operating Expenses USD 99.493 Million - TradingView
Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences announces proposed concurrent public offerings - MSN
272,460 Shares in Cogent Biosciences, Inc. $COGT Acquired by Principal Financial Group Inc. - MarketBeat
How cyclical is Cogent Biosciences Inc.’s revenue streamEarnings Summary Report & Safe Swing Trade Setups - mfd.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Exploring a Potential 43% Upside with Innovative Biotech Approaches - DirectorsTalk Interviews
What are Cogent Biosciences Inc.’s recent SEC filings showingMarket Performance Report & Risk Controlled Stock Pick Alerts - mfd.ru
Cogent Biosciences, Inc. $COGT Shares Bought by Candriam S.C.A. - MarketBeat
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - Investing News Network
Support Test: Is Cogent Biosciences Inc forming a double bottomWatch List & Short-Term Trading Alerts - baoquankhu1.vn
(COGT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Federated Hermes Inc. Purchases 93,223 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Is FDA Breakthrough Status And Rapid Review For Bezuclastinib Reshaping The Case For Cogent Biosciences (COGT)? - Sahm
3.69%
0.68%
자본화:
|
볼륨(24시간):